Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries TriSalus Life Sciences, Inc. - Common Stock (NQ: TLSI ) 5.400 +0.040 (+0.75%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 25,564 Open 5.480 Bid (Size) 5.200 (14) Ask (Size) 5.400 (4) Prev. Close 5.360 Today's Range 5.120 - 5.535 52wk Range 3.320 - 16.24 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation July 01, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants June 26, 2024 From TriSalus Life Sciences Via Business Wire Performance YTD -34.55% -34.55% 1 Month -10.45% -10.45% 3 Month -42.74% -42.74% 6 Month -36.40% -36.40% 1 Year -55.00% -55.00% More News Read More TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting June 03, 2024 From TriSalus Life Sciences Via Business Wire Crude Oil Rises 1%; Verastem Shares Slide May 24, 2024 Via Benzinga Exposures Fossil Fuels Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session May 24, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session May 24, 2024 Via Benzinga Nasdaq Gains 1%; Intuit Shares Plunge May 24, 2024 Via Benzinga TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants May 24, 2024 From TriSalus Life Sciences Via Business Wire TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 May 15, 2024 Via InvestorPlace TriSalus Reports Q1 2024 Financial Results and Business Update May 15, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors May 07, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call May 06, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives April 30, 2024 From TriSalus Life Sciences Via Business Wire TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 April 01, 2024 Via InvestorPlace TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update April 01, 2024 From TriSalus Life Sciences Via Business Wire Earnings Scheduled For April 1, 2024 April 01, 2024 Via Benzinga TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting March 26, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting March 21, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101 March 07, 2024 From TriSalus Life Sciences Via Business Wire TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors February 29, 2024 From TriSalus Life Sciences Via Business Wire 12 Health Care Stocks Moving In Thursday's Intraday Session December 14, 2023 Via Benzinga TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update November 14, 2023 From TriSalus Life Sciences Inc. Via Business Wire TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call November 07, 2023 From TriSalus Life Sciences Inc. Via Business Wire Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications November 04, 2023 From TriSalus Life Sciences Inc. Via Business Wire TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 03, 2023 From TriSalus Life Sciences Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
